The Path to an Angiotensin Receptor Antagonist-Neprilysin Inhibitor in the Treatment of Heart Failure-Reference-Cited by-同舟云学术

The Path to an Angiotensin Receptor Antagonist-Neprilysin Inhibitor in the Treatment of Heart Failure

Published:2015-03 Issue:10 Volume:65 Page:1029-1041
ISSN:0735-1097
Container-title:Journal of the American College of Cardiology
language:en
Short-container-title:Journal of the American College of Cardiology

Author:

Braunwald Eugene

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference116 articles.

1. PARADIGM-HF trial of Novartis' LCZ696 for chronic heart failure closes early based on strength of interim results. Novartis press release. March 31, 2014. Available at: http://www.novartis.com/newsroom/media-releases/en/2014/1772754.shtml. Accessed January 19, 2015.

2. Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact

3. Baseline characteristics and treatment of patients in Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF);McMurray;Eur J Heart Fail,2014

4. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure;N Engl J Med,1991

Cited by 133 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and Safety of Sacubitril/Valsartan in Adverse Cardiovascular Event Reduction and Hypertension Control Among Asians: A Systematic Review and Meta-analysis of Randomized Controlled Trials;Philippine Journal of Cardiology;2024-06-15

2. Impact of Treatment With Sacubitril/Valsartan on Erectile Dysfunction in Patients With Heart Failure With Reduced Ejection Fraction;The American Journal of Cardiology;2024-02

3. Reverse Remodeling Effects of Sacubitril-Valsartan: Structural and Functional Optimization in Stage C Heart Failure;The American Journal of Cardiology;2024-01

4. Decrypting the role of angiogenesis, inflammation, and oxidative stress in pathogenesis of congestive heart failure: Nanotechnology as a boon for the management of congestive heart failure;Targeting Angiogenesis, Inflammation, and Oxidative Stress in Chronic Diseases;2024

5. Long Non-Coding RNAs (lncRNAs) in Heart Failure: A Comprehensive Review;Non-Coding RNA;2023-12-28